<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2895">
  <stage>Registered</stage>
  <submitdate>31/08/2010</submitdate>
  <approvaldate>31/08/2010</approvaldate>
  <nctid>NCT01193257</nctid>
  <trial_identification>
    <studytitle>Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-018662-23</secondaryid>
    <secondaryid>C21005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Orteronel + prednisone
Treatment: drugs - Placebo + prednisone

Experimental: Orteronel + prednisone - 

Placebo Comparator: Placebo + prednisone - 


Treatment: drugs: Orteronel + prednisone
Orteronel and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented

Treatment: drugs: Placebo + prednisone
Placebo and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival (OS) - Patients will be followed for survival until 80% of patients have died or are lost to follow-up</outcome>
      <timepoint>Time from patient randomization to death from any cause</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>50% prostate specific antigen (PSA) response at 12 weeks</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain response at 12 weeks</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Radiographic progression-free survival (rPFS)</outcome>
      <timepoint>Time from patient randomization to radiographic disease progression or death from any cause, whichever occurs first</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Each patient must meet all of the following inclusion criteria:

          -  Voluntary written consent

          -  Male patients 18 years or older

          -  Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma

          -  Radiograph-documented metastatic disease

          -  Progressive disease

          -  Prior surgical castration or concurrent use of an agent for medical castration

          -  Have progressive disease during or following 1 or 2 regimens of cytotoxic
             chemotherapy, 1 of which must have included docetaxel. Must have received = 360 mg/m2
             of docetaxel within a 6-month period. Patients who were clearly intolerant to
             docetaxel or develop progressive disease before receiving = 360 mg/m2 are also
             eligible if they have received at least 225 mg/m2 of docetaxel within a 6-month period
             and meet the other study entry criteria.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Even if surgically sterilized, patients must Practice effective barrier contraception
             during the entire study treatment period and for 4 months after the last dose of study
             drug, OR Abstain from heterosexual intercourse

          -  Meet screening laboratory values as specified in protocol

          -  Stable medical condition

          -  Life expectancy of 6 months or more

          -  Patients who have had up to 2 prior chemotherapy treatments are eligible to
             participate</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone
             (GnRH) analogue

          -  Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone

          -  Any other therapies for prostate cancer, except for GnRH analogue therapy, must be
             discontinued 2 weeks before the first dose of study drug

          -  Radioisotope therapy or external beam radiation therapy within 4 weeks of first dose
             of study drug

          -  Documented central nervous system metastases

          -  Treatment with any investigational compound within 30 days prior ro first dose of
             study drug (Patients who are in long-term follow-up following active treatment in
             other trials are eligible)

          -  Diagnosis or treatment of another malignancy within 2 years preceding first dose of
             study drug except nonmelanoma skin cancer or in situ malignancy completely resected

          -  Uncontrolled cardiovascular condition as specified in study protocol

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  Unwilling or unable to comply with protocol

          -  Known gastrointestinal disease or procedure that could interfere with oral absorption
             or tolerance of orteronel

          -  Uncontrolled nausea, vomiting, or diarrhea despite appropriate medical therapy

          -  Patients whose prostate cancer is confined to just the prostrate bed or immediate
             adjacent tissue</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1099</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,TAS,VIC</recruitmentstate>
    <hospital> - Redcliffe</hospital>
    <hospital> - Woodville South</hospital>
    <hospital> - Hobart</hospital>
    <hospital> - Malvere</hospital>
    <hospital> - Wodonga</hospital>
    <postcode> - Redcliffe</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Malvere</postcode>
    <postcode> - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Kortijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Dralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kromertz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Modrice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche-sur-Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Osztaly</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bielsko-Biala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Goczalkowice-Zdroj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Millennium Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus
      prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant
      prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01193257</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Millennium Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>